At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Mesna, and 6 other interventions for Myeloid Malignancies and 3 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). KDS-1001 is a study product created using certain immune cells called natural killer (NK) cells collected from a third-party donor.
Study Details
Timeline
Interventions
Given by IV
Given by IV
Given by IV
Given by IV
Given by IV
Given by IV
Given by IV
Given by IV